Eton PharmaceutcialsETON
ETON
About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Employees: 31
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
5,619% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $69K
800% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 3
207% more capital invested
Capital invested by funds: $57M [Q3] → $175M (+$118M) [Q4]
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
49% more funds holding
Funds holding: 47 [Q3] → 70 (+23) [Q4]
12.51% more ownership
Funds ownership: 36.8% [Q3] → 49.31% (+12.51%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
42%
upside
Avg. target
$28
64%
upside
High target
$33
96%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker 50% 1-year accuracy 13 / 26 met price target | 54%upside $26 | Buy Maintained | 19 Mar 2025 |
B. Riley Securities Madison El-Saadi 60% 1-year accuracy 3 / 5 met price target | 42%upside $24 | Buy Reiterated | 19 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 190 met price target | 96%upside $33 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
Neutral
GlobeNewsWire
4 weeks ago
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A.
Neutral
GlobeNewsWire
1 month ago
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON's net sales.
Neutral
Seeking Alpha
1 month ago
Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q4 2024 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Ipek Trinkaus - Chief Commercial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Operator Good day, and thank you for standing by.
Neutral
Zacks Investment Research
1 month ago
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growth Closed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in January Acquired and relaunched ultra rare disease product Galzin® Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company's pediatric endocrinology pipeline Announced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submission Manufactured ET-400 launch inventory in preparation for a potential approval on its PDUFA goal date of May 28 Management to hold Investor Day conference call today at 10:00am ET to discuss its recent acquisitions and review its product portfolio, market opportunities, and 2025 and long-term financial outlook DEER PARK, Ill., March 18, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 -
Neutral
GlobeNewsWire
1 month ago
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT).
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now available exclusively through Optime Care –
Charts implemented using Lightweight Charts™